| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b8e71233d46c313ac971fc4f9e4aa4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2014-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fabe887699a6c2d80300a009beb14cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07e039a3f28c4f6a263b2fe0171271dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92eb8ffdc3c5990fde45d44762e95674
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6141bbf8a5ed500f49d4edc181368a7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47cf39edfbef2001f6e21b0586c0baa6 |
| publicationDate |
2015-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015044238-A1 |
| titleOfInvention |
Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the c-terminus |
| abstract |
Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of n L v -[(LU) 0-1 -(D) 1-4 ] p n wherein L- is Ligand unit; LU is a Linker unit (LU); v is 1; p is an number ranging from about 1 to about 20; and D is a drug moiety having the formula: n n n n n n n n n n wherein the moiety —N(R 9 )Z 1 is a phenylalanine bioisostere, wherein Z 1 is —CH(R 10 )Z 2 so that the phenylalanine bioisostere has the structure of Formula A: n n n n n n n n n n and wherein the substituents R 2 -R 10 , X 1 and Z 2 are as defined. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10618935-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10233212-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018140275-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10683327-B2 |
| priorityDate |
2005-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |